Nasdaq

Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy 24th Annual Meeting

- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression ...
Business Wire

Akouos Discloses Lead Program, AK-OTOF, a Potential Gene Therapy for Sensorineural Hearing Loss

BOSTON--(BUSINESS WIRE)--Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, today disclosed its lead program, AK-OTOF, a gene therapy focused on ...
KOIN 6

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of ...

- Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical ...
Nasdaq

Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss

-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the first for an AAV vector therapy with the potential to treat an inner ear condition -Akouos plans ...
Nature

Evolution of gene expression

Much of the phenotypic variation that is observed within and between species is the result of differences in gene regulation: specifically when, where and how much the genes are expressed. Given the ...